All Stories

  1. SCAR : The high‐prevalence antigen 013.008 in the Scianna blood group system
  2. Predictive modeling of complex ABO glycan phenotypes by lectin microarrays
  3. Anti‐D selection for D assignment among pregnant women and blood donors: impact of the Crawford antigen
  4. Complement activating ABO anti-A IgM/IgG act synergistically to cause erythrophagocytosis: implications among minor ABO incompatible transfusions
  5. Complement activating ABO IgM/IgG act synergistically to cause erythrophagocytosis: implications among minor ABO incompatible platelet transfusions
  6. It's time to phase out “serologic weak D phenotype” and resolve D types with RHD genotyping including weak D type 4
  7. ABO titers: harmonization and identifying clinically relevant ABO antibodies
  8. Fetal inheritance of GP*Mur causing severe HDFN in an unrecognized case of maternal alloimmunization
  9. IgG3 anti‐Kell allotypic variation results in differential antigen binding and phagocytosis
  10. How to use a cloud‐based search engine of a centralized donor database to identify historical antigen‐negative units in hospital inventories
  11. Use of a cloud‐based search engine of a centralized donor database to identify historical antigen‐negative units in hospital inventories
  12. Performance and reliability of a benchtop automated instrument for transfusion testing: a comparative multicenter clinical study in the US population
  13. Mass-scale red cell genotyping of blood donors: from data visualization to historical antigen labeling and donor recruitment
  14. New RHCE*ce variant allele in African descent holds 105C > T (silent) in cis to 48C in Exon 1 and 733G in Exon 5
  15. Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline
  16. Acquired red cell defects of the regulators of complement activation.
  17. Trends in antigen-negative red blood cell distributions by racial or ethnic groups in the United States
  18. The first reported case of concurrent trimethoprim-sulfamethoxazole-induced immune hemolytic anemia and thrombocytopenia
  19. 2015 conference on blood group genetics in the era of precision medicine.
  20. How do I work up pretransfusion samples containing anti-CD38?
  21. Genetic background of the rare Yus and Gerbich blood group phenotypes: homologous regions of the GYPC gene contribute to deletion alleles
  22. Molecular characterization of three novel weak D type alleles with additional haplotype data on weak D Types 1.2 and 18
  23. Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy
  24. Cost-effectiveness of implementing molecular immunohematology
  25. TheDAUcluster: a comparative analysis of 18RHDalleles, some forming partial D antigens
  26. Unusual serological findings associated with ceftriaxone-induced immune hemolytic anemia in a child with disseminated low-grade glioma
  27. RHCE*cE94Gencodes variable expression of c (RH4)
  28. Integration of red cell genotyping into the blood supply chain: a population-based study
  29. Implementing mass-scale red cell genotyping at a blood center
  30. A multicenter study on the performance of a fully automated, walk-away high-throughput analyzer for pretransfusion testing in the US population
  31. Barriers to using molecularly typed minority red blood cell donors in support of chronically transfused adult patients with sickle cell disease
  32. The future of red blood cell alloimmunization risk reduction
  33. It's time to phase inRHDgenotyping for patients with a serologic weak D phenotype
  34. RhD Specific Antibodies Are Not Detectable in HLA-DRB11501*Mice Challenged with Human RhD Positive Erythrocytes
  35. Prospects for the provision of genotyped blood for transfusion
  36. Antibody‐mediated glycophorin C coligation on K562 cells induces phosphatidylserine exposure and cell death in an atypical apoptotic process
  37. Allo- and autoanti-D in weak D types and in partial D
  38. Microfluidic approach to genotyping human platelet antigens
  39. Mass-scale high-throughput multiplex polymerase chain reaction for human platelet antigen single-nucleotide polymorphisms screening of apheresis platelet donors
  40. DNA-based methods in the immunohematology reference laboratory
  41. Editorial Comment
  42. Molecular basis of blood group expression
  43. Mass-scale red cell genotyping of blood donors
  44. Titers of ABO antibodies in group O blood donors
  45. Anti-glycophorin C induces mitochondrial membrane depolarization and a loss of extracellular regulated kinase 1/2 protein kinase activity that is prevented by pretreatment with cytochalasin D: implications for hemolytic disease of the fetus and newborn ca
  46. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models?
  47. The proximal cis-regulatory region of theRHD/RHCEpromoter is 105 bp and contains a 55-bp core devoid of known binding motifs but necessary for transcription
  48. Genotyping for red blood cell polymorphisms
  49. Single Base Extension in Multiplex Blood Group Genotyping
  50. Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time
  51. Hemolytic Disease of the Fetus and Newborn Due to Anti-Ge3: Combined Antibody-Dependent Hemolysis and Erythroid Precursor Cell Growth Inhibition
  52. IFN-γ treated monocyte/macrophage phagocytosis of red cells sensitized with IgG1 and IgG3 Anti-D containing identical immunoglobulin variable region genes
  53. The Development of a Bacteriophage Expression Vector for Cloning Immunoglobulin Variable Region Genes from B-Cell Genomic DNAa
  54. Rh discrepancies caused by variable reactivity of partial and weak D types with different serologic techniques
  55. On the Complexity of D Antigen Typing: A Handy Decision Tree in the Age of Molecular Blood Group Diagnostics
  56. Fetal blood group genotyping
  57. Small world – Advance of microarrays: Current status and future trends
  58. The above letter was sent to Branch et al.; Drs Branch and Denomme offered the following reply.
  59. Predictive blood group genetics in hemolytic disease of the fetus and newborn: a 10-year review of a laboratory evaluation of amniotic fluid-derived DNA
  60. Detection of antibodies reacting with the antithetical duffy blood group antigens Fya and Fyb using recombinant fusion proteins containing the duffy extracellular domain
  61. Antenatal administration of Rh-immune globulin causes significant increases in the immunomodulatory cytokines transforming growth factor-β and prostaglandin E2
  62. Inhibition of erythroid progenitor cell growth by anti-Ge3
  63. Amino-acid substitution in the disordered loop of blood group B-glycosyltransferase enzyme causes weak B phenotype
  64. High-throughput multiplex single-nucleotide polymorphism analysis for red cell and platelet antigen genotypes
  65. Chemical compounds that target thiol-disulfide groups on mononuclear phagocytes inhibit immune mediated phagocytosis of red blood cells
  66. ABO sequence analysis in a family with weak expression of blood group B
  67. Maternal ABO-mismatched blood for intrauterine transfusion of severe hemolytic disease of the newborn due to anti-Rh17
  68. Acute intravascular hemolysis after the infusion of a chimeric red blood cell unit
  69. The structure and function of the molecules that carry human red blood cell and platelet antigens☆
  70. A simple and rapid competitive enzyme-linked immunosorbent assay to identify HPA-1a (PlA1)-negative donor platelet units
  71. Fcγ receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura
  72. Novel 3' Rhesus box sequences confound RHD zygosity assignment
  73. Synonymous nucleotide substitutions in the neonatal Fc receptor
  74. RhD status of a fetus at risk for haemolytic disease with a discrepant maternal DNA-based RhD genotype
  75. An Adenine Trimer Precedes a C/G Polymorphism in the 3′-Amplimer Region of the Human Platelet Glycoprotein IIIa Intron 6 CT Repeat
  76. Activation of platelets by sera containing igg1 heparin-dependent antibodies: an explanation for the predominance of the Fcγrlla “low responder” (his131) gene in patients with heparin-induced thrombocytopenia
  77. Maternal immunization to Gov system alloantigens on human platelets
  78. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry
  79. The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis
  80. The cDNA Sequence of Human Endothelial Cell Multimerin
  81. The role of the immunoglobulin heavy chain in human anti-dna antibody binding specificity
  82. Immunoglobulin V Sequences of Two Human Antiplatelet Monoclonal Autoantibodies Derived from B Cells of Normal Origin
  83. Immunoglobulin V region heavy and light chain gene sequences of the lymphoblastoid cell line GM 4672
  84. The production of human monoclonal antiplatelet auto-antibodies derived from human lymphocytes of normal origin: reactivity to DNA, anionic phospholipids and platelet proteins
  85. Comparison of the measurement of surface or total platelet-associated IgG in the diagnosis of immune thrombocytopenia
  86. The production of platelet controls for assays quantitating platelet- associated IgG
  87. Immune-mediated thrombocytopenia of malaria.
  88. The Measurement of Plateiet-Associated IgG Using an Immunoradiometric Assay